INC. (NASDAQ:INCR) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

INC. (NASDAQ:INCR) Files An 8-K Results of Operations and Financial Condition
Item 2.02.Results of Operations and Financial Condition.

On July 21, 2020, Capital City Bank Group, Inc. (“CCBG”) issuedan earnings press release reporting CCBG’sfinancial
results for the three and six month period ended June 30,2020.A copy of the press release is attached as Exhibit 99.1 heretoand
incorporated herein by reference.
The information furnished under Item 2.02 of this Current Report,including the Exhibit attached hereto, shall not be deemed
“filed” for purposes of Section 18 of the Securities ExchangeAct of 1934, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, except as shall be expressly setforth by specific reference in such filing.
Item 9.01.Financial Statements and Exhibits.
(d)
Exhibits
.
Item No.Description of Exhibit
99.1Press release, dated July 21, 2020.
CAPITAL CITY BANK GROUP INC Exhibit
EX-99.1 2 exhibit991.htm EXHIBIT 99.1 exhibit991   Capital City Bank Group,…
To view the full exhibit click here

About INC. (NASDAQ:INCR)

INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.